Skip to main content

Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma

International Journal of Clinical Oncology volume 16, pages 352–358 (2011)Cite this article

Abstract

Background

Galectin-3 (Gal-3) is a β-galactoside-binding lectin involved in regulating cell growth, angiogenesis, and tumor progression. We investigated the clinical significance of Gal-3 expression including its possible use as a prognostic marker or therapeutic target in epithelial ovarian carcinoma (EOC).

Methods

Gal-3 expression was evaluated by immunohistochemistry in 71 patients with 54 serous, 13 endometrioid, and 4 mucinous ovarian carcinomas. We assessed the correlation of Gal-3 expression with clinical characteristics including histology, optimal debulking, chemosensitivity, and survival. In vitro, Gal-3 was inhibited using siRNA to evaluate its role in cell growth and sensitivity to chemotherapeutic agents in ovarian carcinoma cell lines.

Results

Gal-3 protein, which was mainly cytoplasmic in location, was observed in a majority (63/71, 88.7%) of the EOCs but not in normal ovarian tissues (P < 0.001). High Gal-3 expression in EOCs correlated with shorter progression-free survival (PFS) of patients (P = 0.039; 43.1 and 49.5 months, respectively). Moreover, cotreatment with Gal-3 siRNA and paclitaxel showed an enhanced cytotoxic effect compared with control siRNA in SKOV3 cells.

Conclusion

These findings suggest that Gal-3 expression can be a prognostic factor for PFS and may be involved in regulating the response to paclitaxel-based chemotherapy in the treatment of EOC.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    PubMed  Article  Google Scholar 

  2. Kim K, Ryu SY (2009) Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol 20:198

    PubMed  Article  Google Scholar 

  3. Banerjee S, Gore M (2009) The future of targeted therapies in ovarian cancer. Oncologist 14:706–716

    PubMed  Article  CAS  Google Scholar 

  4. Barondes SH, Cooper DN, Gitt MA et al (1994) Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810

    PubMed  CAS  Google Scholar 

  5. Hirabayashi J, Kasai K (1993) The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 3:297–304

    PubMed  Article  CAS  Google Scholar 

  6. Elola MT, Wolfenstein-Todel C, Troncoso MF et al (2007) Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64:1679–1700

    PubMed  Article  CAS  Google Scholar 

  7. Le Mercier M, Fortin S, Mathieu V et al (2010) Galectins and gliomas. Brain Pathol 20:17–27

    PubMed  Article  CAS  Google Scholar 

  8. Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17

    PubMed  Article  Google Scholar 

  9. Davidson PJ, Li SY, Lohse AG et al (2006) Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import. Glycobiology 16:602–611

    PubMed  Article  CAS  Google Scholar 

  10. Ochieng J, Furtak V, Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19:527–535

    PubMed  Article  Google Scholar 

  11. Matarrese P, Fusco O, Tinari N et al (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554

    PubMed  Article  CAS  Google Scholar 

  12. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742

    PubMed  Article  CAS  Google Scholar 

  13. Akahani S, Nangia-Makker P, Inohara H et al (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272–5276

    PubMed  CAS  Google Scholar 

  14. Bresalier RS, Mazurek N, Sternberg LR et al (1998) Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115:287–296

    PubMed  Article  CAS  Google Scholar 

  15. van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19:537–542

    PubMed  Article  Google Scholar 

  16. van den Brule FA, Berchuck A, Bast RC et al (1994) Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A:1096–1099

    PubMed  Article  Google Scholar 

  17. Brustmann H (2008) Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 27:380–389

    PubMed  Article  Google Scholar 

  18. Oishi T, Itamochi H, Kigawa J et al (2007) Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17:1040–1046

    PubMed  Article  CAS  Google Scholar 

  19. Saussez S, Decaestecker C, Mahillon V et al (2008) Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 118:1583–1590

    PubMed  Article  CAS  Google Scholar 

  20. Lee JW, Lee SJ, Seo J et al (2005) Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol 97:53–59

    PubMed  Article  CAS  Google Scholar 

  21. Shimonishi T, Miyazaki K, Kono N et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310

    PubMed  Article  CAS  Google Scholar 

  22. Nakahara S, Raz A (2008) Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 8:22–36

    PubMed  Article  CAS  Google Scholar 

  23. Nangia-Makker P, Hogan V, Honjo Y et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862

    PubMed  CAS  Google Scholar 

  24. Bresalier RS, Yan PS, Byrd JC et al (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer (Phila) 80:776–787

    Article  CAS  Google Scholar 

  25. Schoeppner HL, Raz A, Ho SB et al (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer (Phila) 75:2818–2826

    Article  CAS  Google Scholar 

  26. Miyazaki J, Hokari R, Kato S et al (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312

    PubMed  CAS  Google Scholar 

  27. Davidson PJ, Davis MJ, Patterson RJ et al (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337

    PubMed  Article  CAS  Google Scholar 

  28. Takenaka Y, Fukumori T, Raz A (2004) Galectin-3 and metastasis. Glycoconj J 19:543–549

    PubMed  Article  Google Scholar 

  29. Balasubramanian K, Vasudevamurthy R, Venkateshaiah SU et al (2009) Galectin-3 in urine of cancer patients: stage and tissue specificity. J Cancer Res Clin Oncol 135:355–363

    PubMed  Article  CAS  Google Scholar 

  30. Lin CI, Whang EE, Abramson MA et al (2009) Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379:626–631

    PubMed  Article  CAS  Google Scholar 

  31. Guess BW, Scholz MC, Strum SB et al (2003) Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 6:301–304

    PubMed  Article  CAS  Google Scholar 

  32. Takei Y, Kadomatsu K, Yuzawa Y et al (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64:3365–3370

    PubMed  Article  CAS  Google Scholar 

  33. Hingorani SR, Jacobetz MA, Robertson GP et al (2003) Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63:5198–5202

    PubMed  CAS  Google Scholar 

  34. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247

    PubMed  Article  CAS  Google Scholar 

  35. Glinsky VV, Kiriakova G, Glinskii OV et al (2009) Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11:901–909

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the Korea Health 21 R&D Project of the Ministry of Health & Welfare, Republic of Korea (A090088).

Conflict of interest

No author has any conflict of interest.

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, Korea

    Min Kyu Kim, Hye-Kyung Jeon, Tae Jong Song, Hwang Shin Park, Yoo-Young Lee, Byoung-Gie Kim, Jeong-Won Lee & Duk-Soo Bae

  2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Chang Ohk Sung

  3. Experimental Pathology Center, Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea

    In-Gu Do

Authors
  1. Min Kyu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang Ohk Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. In-Gu Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hye-Kyung Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tae Jong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hwang Shin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoo-Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Byoung-Gie Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeong-Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Duk-Soo Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jeong-Won Lee or Duk-Soo Bae.

Additional information

M. K. Kim and C. O. Sung contributed equally to this paper.

This abstract was chosen as a poster presentation at 2010 IGCS (International Gynecologic Cancer Society) (A-214-0003-01288).

About this article

Cite this article

Kim, M.K., Sung, C.O., Do, IG. et al. Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16, 352–358 (2011). https://doi.org/10.1007/s10147-011-0190-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-011-0190-x

Keywords

  • Galectin-3
  • Ovarian carcinoma
  • siRNA
  • Chemosensitivity
  • Molecular target